<DOC>
	<DOCNO>NCT01535573</DOCNO>
	<brief_summary>This phase 2 clinical trial citalopram pharmacotherapy treatment cocaine dependence . Using double-blind , randomize control design , eligible cocaine dependent patient assign equally one three medication condition : placebo Selective serotonin re-uptake inhibitor ( SSRI ) agent , citalopram either 20 mg per day 40 mg per day . It hypothesize citalopram reduce cocaine use increase period sustain abstinence substantially placebo . Performance set behavioral task impulsivity analyze potential predictor treatment response .</brief_summary>
	<brief_title>Citalopram Cocaine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>18 60 year age meet Diagnostic Statistical Manual 4 ( DSMIV ) criteria current cocaine dependence acceptable health basis interview , medical history physical exam able provide name least 2 person generally locate whereabouts . diagnosis psychoactive substance dependence cocaine , marijuana , nicotine psychiatric disorder neurological disease disorder require ongoing treatment and/or make study participation unsafe medical condition contraindicate citalopram pharmacotherapy take medication know significant drug interaction study medication pregnant nursing female patient plan leave immediate geographical area within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cocaine</keyword>
	<keyword>citalopram</keyword>
	<keyword>treatment</keyword>
	<keyword>serotonin</keyword>
</DOC>